10 results
(1) investigating the influence of modafinil on fatigue, cognitive functioning, and quality of life of LGG patients, (2) assessing the correlation between (changes in) fatigue, cognition, and quality of life on the one hand, and functional…
· Evaluate the efficacy and safety of BF2.649 administered by escalating doses and followed by 5-week stable doses in narcoleptic patients with excessive daytime sleepiness (EDS) as compared to placebo.· Evaluate the efficacy and safety of BF2.649…
The goals of the proposed study are: (1) to further elucidate the relations between impulse control, motivational strength of drug cues, and brain activation patterns (using fMRI); (2) to examine the relative strength by which these processes are…
Evaluate and compare the efficacy and safety of escalating doses of BF2.649 and BF2.649 add on Modafinil on cataplexy attacks.Evaluate the additive/synergistic effect of the combination of BF2.649 and Modafinil on excessive daytime sleepiness (EDS…
The primary objective of this study is to further evaluate the safety and tolerability of pegaptanib sodium in subjects with DME.
The purpose of this study is to investigate how safe modafinil is and how well it is tolerated when it is administered in combination with aniracetam to generally healthy elderly volunteers with subjective cognitive decline. Modafinil and aniracetam…
The objective of this study is to assess the distribution of infusion associated reactions (IARs) by severity grade when Lemtrada is administered to RRMS patients who will be medicated according to specified algorithm designed to manage infusion…
To evaluate the long-term safety and efficacy of alemtuzumab, for patients already treated with this medicine in preceding clinical trials (CARE-MS I, CARE-MS II and CAMMS03409).
The objective of this prospective, randomized study is to investigate the efficacy and safety of HSCT compared to the comparator group (alemtuzumab, cladribine or ocrelizumab) in patients with aggressive relapsing remitting MS. In Norway, the…
Primary objective:To evaluate the efficacy, safety and tolerability of alemtuzumab intravenously (IV) in paediatric patients from 10 to <18 years of age with relapsing remitting multiple sclerosis (RRMS) who have disease activity on prior…